Elahere

(Mirvetuximab Soravtansine)

Phase 3Antibody–drug conjugate

This drug is used to treat a type of ovarian cancer called folate receptor alpha-positive ovarian cancer. It works by delivering a toxic substance directly to cancer cells that have a specific marker on their surface.[1] Elahere is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]

Elahere is one of 84 small molecule programs targeting Ovarian Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Ovarian NeoplasmUnknown

Malignant Epithelial Tumor of OvaryUnknown

Fallopian Tube NeoplasmUnknown

Peritoneal NeoplasmUnknown

PROCNot yet recruiting

Recurrent Ovarian CancerActive, not recruiting

Ovarian CancerUnknown status

Fallopian Tube CancerCompleted

Ovarian NeoplasmPreclinical

Unknown

Malignant Epithelial Tumor of OvaryPreclinical

Unknown

Fallopian Tube NeoplasmPreclinical

Unknown

Peritoneal NeoplasmPreclinical

Unknown

PROCPhase 2

Not yet recruiting

Recurrent Ovarian CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Unknown status

Fallopian Tube CancerPhase 3

Completed

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Keytruda

Merck & Co.

Phase 3

28 4

Hycamtin

MMeitheal

Phase 3

26 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 6

Femara

Novartis

Phase 3

8 7

Imfinzi

AstraZeneca

Phase 3

8 8

Opdivo

Bristol-Myers Squibb

Phase 3

8 9

Adriamycin

Pfizer

Phase 3

8 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT05456685

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Q1 2027

Phase 2Active, not recruiting

Recurrent Ovarian Cancer

NCT06365853

Q1 2028

Phase 2Recruiting

Fallopian Tube Cancer

NCT06682988

Q2 2028

Phase 2Not yet recruiting

PROC

NCT07741630

Phase 2Recruiting

Ovarian Cancer

NCT04606914

Clinical

Trials by Indication[1]

Ovarian Cancer7 trials

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Unknown status·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT05622890·35 enrolled

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Completed·IImmunoGen, Inc.·Phase 1·NCT01609556·206 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Show 4 more trials

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT05456685·125 enrolled

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07059845·400 enrolled

A Real-world Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (MIRV) in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer With Expression of Folate Receptor α（FRα）

Not yet recruiting·NNING LI-GYN··NCT07690332·400 enrolled

Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04606914·70 enrolled

Fallopian Tube Cancer6 trials

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Completed·IImmunoGen, Inc.·Phase 1/2·NCT02606305·264 enrolled

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Completed· AbbVie logo

AbbVie·Phase 2·NCT05041257·79 enrolled

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Completed·IImmunoGen, Inc.·Phase 3·NCT04296890·106 enrolled

Show 3 more trials

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Completed· AbbVie logo

AbbVie·Phase 3·NCT04209855·453 enrolled

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Completed·IImmunoGen, Inc.·Phase 3·NCT02631876·366 enrolled

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06682988·110 enrolled

Breast Cancer2 trials

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03106077·96 enrolled

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed·—·Phase 1·NCT02996825·44 enrolled

Epithelial Ovarian Cancer2 trials

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06890338·140 enrolled

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07218809·1,100 enrolled

Endometrial Cancer1 trial

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Withdrawn·UUniversity of Oklahoma·Phase 2·NCT03836157

5 more indications

TNBC1 trial

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Withdrawn·—·Phase 1·NCT03045393

Primary Peritoneal Cancer1 trial

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT03552471·25 enrolled

Metastatic Pancreatic Adenocarcinoma1 trial

An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07825753·225 enrolled

Recurrent Ovarian Cancer1 trial

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06365853·108 enrolled

PROC1 trial

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

Not yet recruiting·PPeking University Third Hospital·Phase 2·NCT07741630·20 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 14, 2022

ELAHERE

BLA BLA761310

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Mirvetuximab Soravtansine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirvetuximab Soravtansine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirvetuximab Soravtansine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761310). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Immunogenics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Folate Receptor Alpha Binding Agent; Tubulin Inhibitor[2]
Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: IImmunogenics, LLC

Elahere

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Ovarian Cancer7 trials

Fallopian Tube Cancer6 trials

Breast Cancer2 trials

Epithelial Ovarian Cancer2 trials

Endometrial Cancer1 trial

TNBC1 trial

Primary Peritoneal Cancer1 trial

Metastatic Pancreatic Adenocarcinoma1 trial

Recurrent Ovarian Cancer1 trial

PROC1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News